MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
PURPOSE: Recent advances in the biology and treatment of hormone refractory prostate cancer are reviewed. MATERIALS AND METHODS: A MEDLINE literature search of secondary hormonal therapy and chemotherapy for hormone refractory prostate cancer was performed. Recent advances in the biology of hormone refractory prostate cancer, changes in the measurement of response to therapy, and testing of new drugs and combinations of drugs were reviewed. RESULTS: Historically the treatment of hormone refractory prostate cancer has been disappointing. Useful parameters to monitor clinical response have been lacking but perhaps more importantly a scarcity of apparently active drugs has contributed to these results. Recently several developments have improved the outlook for treatment of hormone refractory prostate cancer. Recognition of antiandrogen withdrawal responses has had important ramifications for clinical trial interpretation and patient care. Secondary hormonal therapies, such as alternative antiandrogens and anti-adrenal agents, are well tolerated and can provide significant clinical benefits. Combining prostate specific antigen values with quality of life and measurable disease responses has made clinical trial end points more objective and more clinically relevant for the patient. Furthermore, a better understanding of the biology of hormone refractory prostate cancer, refinements in measuring response to treatment and availability of agents with proved palliative capabilities and/or generating greater than 50% response have all lead to improvements in treatment management. In 2 randomized studies mitoxantrone in combination with steroids has demonstrated significant palliative benefit compared with steroids alone. In phase II studies more than half of patients respond to estramustine combinations with vinblastine, etoposide or paclitaxel. Other novel combinations and new drugs currently are being tested. CONCLUSIONS: Recent advances suggest that available therapies for hormone refractory prostate cancer can have a meaningful impact on the disease. Improving treatment of hormone refractory prostate cancer remains an area of active investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1998) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.48.1.6 · Cited by 2,341
LNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580
HUGGINS, C. (1941) · Archives of Surgery · doi:10.1001/archsurg.1941.01210140043004 · Cited by 1,499
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Angiogenesis and Tumor Metastasis
Zetter, B. R. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.407 · Cited by 1,015
Shyng, S.-L., Lehmann, S., Moulder, K. L., & Harris, D. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.50.30221 · Cited by 704
Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.
Haldar, S., Chintapalli, J., & Croce, C. M. (1996) · PubMed · Cited by 651
Soloway, M. S., Hardeman, S. W., Hickey, D., Todd, B., Soloway, S., Raymond, J., & Moinuddin, M. (1988) · Cancer · doi:10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y · Cited by 631
Bcl2 is the guardian of microtubule integrity.
Haldar, S., Basu, A., & Croce, C. M. (1997) · PubMed · Cited by 599
Porter, A. T., McEwan, A. J. B., Powe, J. E., Reid, R., McGowan, D. G., Lukka, H., Sathyanarayana, J. R., Yakemchuk, V. N., Thomas, G. M., Erlich, L. E., et al. (1993) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(93)90309-j · Cited by 534
Megestrol acetate for the prevention of hot flashes.
Loprinzi, C. L., Michalak, J. C., Quella, S. K., O'Fallon, J. R., Hatfield, A. K., Nelimark, R. A., Dose, A. M., Fischer, T., Johnson, C., Klatt, N. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408113310602 · Cited by 500
p53 Protein Accumulation and Gene Mutation in the Progression of Human Prostate Carcinoma
Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., Eschenbach, A. C. V., & Conti, C. J. (1993) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/85.20.1657 · Cited by 478
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
Denmeade, S. R., Lin, X. S., & Isaacs, J. T. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(199604)28:4<251::aid-pros6>3.0.co;2-g · Cited by 436
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
Yagoda, A., & Petrylak, D. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<1098::aid-cncr2820711432>3.0.co;2-g · Cited by 419
Tannock, I., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L., & Rider, W. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.590 · Cited by 407
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher, H. I., & Kelly, W. K. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1566 · Cited by 405
Di Sant'Agnese, P. A. (1992) · Cancer · doi:10.1002/1097-0142(19920701)70:1+<254::aid-cncr2820701312>3.0.co;2-e · Cited by 387
Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V, Schwartz, M., & Fossa, S. D. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.607 · Cited by 385
Isaacs, J. T., & Coffey, D. S. (1981) · PubMed · Cited by 371
Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome
Kevin Kelly, W., & Scher, H. I. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)36163-3 · Cited by 349
Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.
Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., To, M., & Lawson, D. (1990) · PubMed · Cited by 308
Regulation of prostatic growth and function by peptide growth factors
Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Hittmair, A., Zhang, J., Thurnher, M., Bartsch, G., & Klocker, H. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(199606)28:6<392::aid-pros9>3.0.co;2-c · Cited by 307
Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
Sedlacek, H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., et al. (1996) · International Journal of Oncology · doi:10.3892/ijo.9.6.1143 · Cited by 275
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
Eisenberger, M. A., Simon, R., O'Dwyer, P. J., Wittes, R. E., & Friedman, M. A. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.6.827 · Cited by 267
The Response of Metastatic Adenocarcinoma of the Prostate to Exogenous Testosterone
Fowler, J. E., & Whitmore, W. F. (1981) · Journal of Urology · doi:10.1016/s0022-5347(17)54531-0 · Cited by 261
Hudes, G. R., Greenberg, R., Krigel, R. L., Fox, S., Scher, R., Litwin, S., Watts, P., Speicher, L., Tew, K., & Comis, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1754 · Cited by 256
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher, H. I., Liebertz, C., Kelly, W. K., Mazumdar, M., Brett, C., Schwartz, L., Kolvenbag, G., Shapiro, L., & Schwartz, M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2928 · Cited by 227
Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
Fenton, M. A., Shuster, T. D., Fertig, A., Taplin, M. E., Kolvenbag, G. J. C. M., Bubley, G. J., & Balk, S. P. (1997) · PubMed · Cited by 225
Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., & Moul, J. W. (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)65641-6 · Cited by 225
Pienta, K. J., Redman, B., Hussain, M., Cummings, G., Esper, P. S., Appel, C., & Flaherty, L. E. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2005 · Cited by 220
Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.
Small, E. J., & Vogelzang, N. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.382 · Cited by 207
HIGH DOSE BICALUTAMIDE FOR ANDROGEN INDEPENDENT PROSTATE CANCER: EFFECT OF PRIOR HORMONAL THERAPY
Joyce, R., Fenton, M. A., Rode, P., Constantine, M., Gaynes, L., Kolvenbag, G., DeWolf, W., Balk, S., Taplin, M. E., & Bubley, G. J. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)64039-4 · Cited by 205
Seidman, A. D., Scher, H. I., Petrylak, D., Dershaw, D. D., & Curley, T. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37426-8 · Cited by 200
Induction of Apoptosis by Diethylstilbestrol in Hormone-Insensitive Prostate Cancer Cells
Robertson, C. N., Roberson, K. M., Padilla, G. M., O'Brien, E. T., Cook, J. M., Kim, C.-S., & Fine, R. L. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.13.908 · Cited by 190
Importance of continued testicular suppression in hormone-refractory prostate cancer.
Taylor, C. D., Elson, P., & Trump, D. L. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2167 · Cited by 188
Hormone-refractory (D3) prostate cancer: Refining the concept
Scher, H. I., Steineck, G., & Kevin Kelly, W. (1995) · Urology · doi:10.1016/s0090-4295(99)80182-4 · Cited by 176
Small, E. J., & Carroll, P. R. (1994) · Urology · doi:10.1016/0090-4295(94)90092-2 · Cited by 171
Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
Tannock, I. F. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.7.1013 · Cited by 170
(1996) · PubMed · Cited by 166
Hussain, M., Wolf, M., Marshall, E., Crawford, E. D., & Eisenberger, M. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1868 · Cited by 158
Elo, J. P., Kvist, L. J., Leinonen, K. A., ISOMAA, V. V., Henttu, P. M. A., Lukkarinen, O. A., & Vihko, P. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530589 · Cited by 143
Expression of bcl-2 and the progression of human and rodent prostatic cancers.
Furuya, Y., Krajewski, S., Epstein, J. I., Reed, J. C., & Isaacs, J. T. (1996) · PubMed · Cited by 143
Theodorescu, D., Broder, S. R., Boyd, J. C., Mills, S. E., & Frierson, H. F. (1997) · The Journal of Urology · doi:10.1097/00005392-199707000-00040 · Cited by 139
Sartor, O. A., Cooper, M. R., Weinberger, M., Headlee, D. J., Thibault, A., Tompkins, A. C., Steinberg, S. M., Figg, W. D., Linehan, W. M., & Myers, C. E. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.3.222 · Cited by 134
Dupont, A., Gomez, J., Cusan, L., Koutsilieris, M., & Labrie, F. (1993) · The Journal of Urology · doi:10.1016/s0022-5347(17)35646-x · Cited by 133
Endocrine control of prostate cancer.
Wilding, G. (1995) · PubMed · Cited by 132
Dawson, N. A., & McLeod, D. G. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)67365-8 · Cited by 122
Sella, A., Kilbourn, R. G., Amato, R. J., Bui, C., Zukiwski, A. A., Ellerhorst, J. A., & Logothetis, C. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.683 · Cited by 121
Clinical Trials in Relapsed Prostate Cancer: Defining the Target
Scher, H. I., Mazumdar, M., & Kelly, W. K. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.22.1623 · Cited by 120
Quality of life in prostate cancer patients
Herr, H. W. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.4.207 · Cited by 88
ADVANCES IN ANGIOGENESIS RESEARCH: RELEVANCE TO UROLOGICAL ONCOLOGY
Campbell, S. C. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64090-4 · Cited by 88
Ellerhorst, J. A., Tu, S., Amato, R. J., Finn, L., Millikan, R. E., Pagliaro, L. C., Jackson, A., & Logothetis, C. J. (1997) · PubMed · Cited by 79
Mechanisms of Action and Clinical Uses of Estramustine
Benson, R. C., & Hartley‐Asp, B. (1990) · Cancer Investigation · doi:10.3109/07357909009012056 · Cited by 75
Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
Hudes, G. R., Nathan, F. E., Khater, C., Greenberg, R. H., Gomella, L. G., Stern, C., & McAleer, C. (1995) · PubMed · Cited by 73
Some Limitations of the Radioisotope Bone Scan in Patients With Metastatic Prostatic Cancer
Smith, P. H., Bono, A. V., da Silva, F. C., et al. (1990) · Cancer · doi:10.1002/cncr.1990.66.s5.1009 · Cited by 72
Tumour suppressor genes in prostate cancer
MacGrogan, D., & Bookstein, R. (1997) · Seminars in Cancer Biology · doi:10.1006/scbi.1997.0048 · Cited by 65
Management of progressive metastatic prostate cancer.
Waselenko, J. K., & Dawson, N. A. (1993) · PubMed · Cited by 54
Kreis, W. (1995) · Cancer Investigation · doi:10.3109/07357909509094465 · Cited by 53
Cytotoxicity of ketoconazole in malignant cell lines
Rochlitz, C. F., Damon, L. E., Russi, M. B., Geddes, A. D., & Cadman, E. C. (1988) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00264198 · Cited by 45
Megestrol Acetate in the Treatment of Hormone Refractory Prostate Cancer
Osborn, J. L., Smith, D. C., & Trump, D. L. (1997) · American Journal of Clinical Oncology · doi:10.1097/00000421-199706000-00021 · Cited by 37
Role of prostate-specific antigen as a predictor of outcome in prostate cancer
Blackledge, G. R. P., & Lowery, K. (1994) · The Prostate · doi:10.1002/pros.2990250710 · Cited by 31
The clinical and biological study of androgen independent prostate cancer (AI PCa).
Logothetis, C. J., Hoosein, N. M., & Hsieh, J. (1994) · PubMed · Cited by 31
TREATMENT OF METASTATIC PROSTATE CANCER
Bubley, G. J., & Balk, S. P. (1996) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70363-4 · Cited by 20
Tamoxifen in advanced prostate cancer: An ECOG pilot study
Horton, J., Rosenbaum, C., & Cummings, F. J. (1988) · The Prostate · doi:10.1002/pros.2990120207 · Cited by 20
Lipton (1995) · Pure Amsterdam UMC · doi:10.1002/1097-0142(19950415)75:8 · Cited by 1
Cited by
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationNakahara, T., Takeuchi, M., Kinoyama, I., Minematsu, T., Shirasuna, K., Matsuhisa, A., Kita, A., Tominaga, F., Yamanaka, K., Kudoh, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1343 · Cited by 497
BANDER, N. H., TRABULSI, E. J., KOSTAKOGLU, L., YAO, D., VALLABHAJOSULA, S., SMITH-JONES, P., JOYCE, M. A., MILOWSKY, M., NANUS, D. M., & GOLDSMITH, S. J. (2003) · Journal of Urology · doi:10.1097/01.ju.0000091655.77601.0c · Cited by 263
The Prodrug Platin‐A: Simultaneous Release of Cisplatin and Aspirin
Pathak, R. K., Marrache, S., Choi, J. H., Berding, T. B., & Dhar, S. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201308899 · Cited by 255
Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases
Lam, J. S., Yamashiro, J., Shintaku, I. P., Vessella, R. L., Jenkins, R. B., Horvath, S., Said, J. W., & Reiter, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1842 · Cited by 211
Metadata
- Authors
- OH, W. K., & KANTOFF, P. W.
- Venue
- Journal of Urology
- Published
- 1998-10
- Volume
- 160
- Issue
- 4
- Pages
- 1220-1229
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2016055442
- Cited by
- 260
- References
- 68
- FWCI
- 20.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.